Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Carcinoma, Non-Small-Cell Lung 73Lung Neoplasms 64Breast Neoplasms 63Lymphoma 58Ovarian Neoplasms 51Leukemia 44Sarcoma 43Prostatic Neoplasms 39Multiple Myeloma 36Head and Neck Neoplasms 36Central Nervous System Neoplasms 36Squamous Cell Carcinoma of Head and Neck 32Colorectal Neoplasms 31Carcinoma, Ovarian Epithelial 30Melanoma 29Rectal Neoplasms 28Neoplasm Metastasis 27Uterine Cervical Neoplasms 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lymphoma, Large B-Cell, Diffuse 26Brain Neoplasms 26Urinary Bladder Neoplasms 24Leukemia, Lymphocytic, Chronic, B-Cell 24Leukemia, Myeloid, Acute 23Fallopian Tube Neoplasms 23Endometrial Neoplasms 22Glioblastoma 21Adenocarcinoma of Lung 21Lymphoma, Mantle-Cell 18Gliosarcoma 17

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2sargramostim 1dinutuximab 1Temozolomide 1Isotretinoin 1Irinotecan 1Colony-Stimulating Factors 1Biopsy 13-fluorobenzylguanidine 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × Ganglioneuroblastoma × Clear all
NCT06858501 2026-03-19

Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

Children's Oncology Group

Phase 2 Not yet recruiting
84 enrolled
CNS

Ganglioneuroblastoma

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 2 Active not recruiting
41 enrolled 13 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡